{
    "organizations": [],
    "uuid": "b3a45e624b4c51a4def0a1e601660bebd52d4cb6",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-acelrx-receives-positive-chmp-opin/brief-acelrx-receives-positive-chmp-opinion-for-dzuveo-for-management-of-acute-moderate-to-severe-pain-in-medically-monitored-settings-idUSFWN1S40Z3",
    "ord_in_thread": 0,
    "title": "BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In Medically Monitored Settings",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 27 (Reuters) - AcelRx Pharmaceuticals Inc:\n* ACELRX RECEIVES POSITIVE CHMP OPINION FOR DZUVEOâ„¢ FOR MANAGEMENT OF ACUTE MODERATE TO SEVERE PAIN IN MEDICALLY MONITORED SETTINGS\n* ACELRX PHARMACEUTICALS INC - RESUBMISSION OF NEW DRUG APPLICATION FOR DSUVIA (KNOWN AS DZUVEO IN EUROPE) TO FDA IN U.S. IS PLANNED FOR Q2 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-27T19:22:00.000+03:00",
    "crawled": "2018-04-28T12:59:13.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "acelrx",
        "pharmaceutical",
        "inc",
        "acelrx",
        "receives",
        "positive",
        "chmp",
        "opinion",
        "management",
        "acute",
        "moderate",
        "severe",
        "pain",
        "medically",
        "monitored",
        "setting",
        "acelrx",
        "pharmaceutical",
        "inc",
        "resubmission",
        "new",
        "drug",
        "application",
        "dsuvia",
        "known",
        "dzuveo",
        "europe",
        "fda",
        "planned",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}